Title
Racial/ethnic heterogeneity in associations of blood pressure and incident cardiovascular disease by functional status in a prospective cohort: the Multi-Ethnic Study of Atherosclerosis.

Permalink
https://escholarship.org/uc/item/7cd07312

Journal
BMJ open, 8(2)

ISSN
2044-6055

Authors
Kaiser, Paulina
Peralta, Carmen A
Kronmal, Richard
et al.

Publication Date
2018-02-23

DOI
10.1136/bmjopen-2017-017746

Peer reviewed
Racial/ethnic heterogeneity in associations of blood pressure and incident cardiovascular disease by functional status in a prospective cohort: the Multi-Ethnic Study of Atherosclerosis

Paulina Kaiser,1 Carmen A. Peralta,2 Richard Kronmal,3 Michael G. Shlipak,2,4 Bruce M Psaty,5 Michelle C Odden1

ABSTRACT

Objectives Research has demonstrated that the association between high blood pressure and outcomes is attenuated among older adults with functional limitations, compared with healthier elders. However, it is not known whether these patterns vary by racial/ethnic group. We evaluated race/ethnicity-specific patterns of effect modification in the association between blood pressure and incident cardiovascular disease (CVD) by functional status.

Setting We used data from the Multi-Ethnic Study of Atherosclerosis (2002–2004, with an average of 8.8 years of follow-up for incident CVD). We assessed effect modification of systolic blood pressure and cardiovascular outcomes by self-reported physical limitations and by age.

Participants The study included 6117 participants (aged 46 to 87; 40% white, 27% black, 22% Hispanic and 12% Chinese) who did not have CVD at the second study examination (when self-reported physical limitations were assessed).

Outcome measures Incident CVD was defined as an incident myocardial infarction, coronary revascularisation, resuscitated cardiac arrest, angina, stroke (fatal or non-fatal) or death from CVD.

Results We observed weaker associations between systolic blood pressure (SBP) and CVD among white adults with physical limitations (incident rate ratio (IRR) per 10 mm Hg higher SBP: 1.09 (95% CI 0.99 to 1.20)) than those without physical limitations (IRR 1.29 (1.19, 1.40); P value for interaction <0.01). We found a similar pattern among black adults. Poor precision among the estimates for Hispanic or Chinese participants limited the findings in these groups. The attenuated associations were consistent across both multiplicative and additive scales, though physical limitations showed clearer patterns than age on an additive scale.

Conclusion Attenuated associations between high blood pressure and incident CVD were observed for blacks and whites with poor function, though small sample sizes remain a limitation for identifying differences among Hispanic or Chinese participants. Identifying the characteristics that distinguish those in whom higher SBP is associated with less risk of morbidity or mortality may inform our understanding of the consequences of hypertension among older adults.

INTRODUCTION

High blood pressure (systolic blood pressure (SBP) ≥140 mm Hg or diastolic blood pressure (DBP) ≥90 mm Hg or taking anti-hypertensive medicine) is a major cause of morbidity and mortality among American adults, and is responsible for an estimated US$48.6 billion in direct and indirect costs per year.1 However, the health risks associated with high blood pressure are not uniform in all adults; some subgroups have been identified in which elevated blood pressure is not associated with increased morbidity or mortality. For example, among older adults with poor functional status, measured by slow gait speed2 3 or by functional limitations, the association between high blood pressure and mortality is attenuated compared with elders with better functional status.4 Interestingly,
in this latter study, the effect modification of blood pressure and mortality by functional status was less apparent in middle-aged participants.\textsuperscript{4} There are limited data on functional status as an effect modifier of blood pressure and cardiovascular outcomes; existing studies have been limited to older adults.\textsuperscript{5,6} Thus, it is not yet clear how age and functional limitations pattern risks of cardiovascular disease (CVD) associated with elevated SPB.

Additionally, it is plausible that the patterns of blood pressure, functional status and morbidity vary by racial/ethnic group. Previous research has demonstrated patterns of attenuation in populations of Latinos\textsuperscript{7} and populations of white Americans and African Americans.\textsuperscript{4,5} Race/ethnicity, as a proxy for biological characteristics as well as lifelong contextual influences, cultural norms and cumulative stressors,\textsuperscript{7} is associated with blood pressure levels and with rates of CVD. For example, a 10 mm Hg higher SPB level is associated with a larger increase in stroke risk for blacks than for whites.\textsuperscript{8} Our objective was to explore racial/ethnic heterogeneity in the interaction of blood pressure and functional status on incident CVD.

### METHODS

#### Study population

We used data from the Multi-Ethnic Study of Atherosclerosis (MESA) to explore race/ethnicity-specific patterns of effect modification in the association between blood pressure and incident CVD by physical limitations and by age. MESA includes 6814 adults aged 45–84 who self-identified as white, black, Hispanic or Chinese from six areas across the USA (New York, New York; Baltimore, Maryland; Forsyth County, North Carolina; Chicago, Illinois; St Paul, Minnesota; and Los Angeles, California). White participants were recruited at all sites; black participants were recruited at all sites except for Minnesota. Hispanic participants came from New York, Minnesota and California, and Chinese participants came from Chicago and California. Participants were excluded if they had a history of heart attack, angina, stroke or transient ischaemic attack, heart failure, resuscitated cardiac arrest or procedures related to CVD. Participants were followed from 2000–2002 until 2010–2012, with a total of five study examinations. Retention was 92.4% from the first examination to the second examination, and 75.7% from the fourth examination to the final examination.\textsuperscript{9} The participants provided informed consent.\textsuperscript{10}

#### Exposure: SBP

Blood pressure was measured at each examination, following a standardised protocol. After 5 min of seated rest, SBP and DBP were measured three times, at 2 min intervals, using an automated oscillometric sphygmomanometer.\textsuperscript{11} The average of the second and third measurements was used for analysis. We used SBP measured at the second examination (2002–2004) as the primary exposure of interest because physical limitations were not assessed at the baseline examination.

#### Effect modifiers

We used two effect modifiers for this analysis: self-reported physical limitations and age. Physical limitations were assessed at examination 2, in 2002–2004, and measured with two questions based off the same prompt: ‘During the past 4 weeks, have you had any of the following problems with your work or other regular daily activities as a result of your physical health?’ Participants were considered to have physical limitations if they answered ‘yes’ to either ‘You accomplished less than you would have liked to’ or ‘You were limited in the kind of work you do or other regular daily activities.’

As a secondary analysis, we used summary scores from a modified version of the 12-Item Short Form Health Survey (SF-12) (version 2)\textsuperscript{12} to measure overall physical health and well-being. The SF-12 survey is a shortened version of the SF-36 scale and has been validated in a variety of settings.\textsuperscript{13,14} The Physical Component Summary score (SF12-P) is a weighted average of questions about general health, limitations in moderate activities or climbing stairs, physical limitations, emotional limitations, pain interfering with work, feeling downhill and blue and health interfering with social activities. SF12-P scores range from 0 to 100 (higher scores represent better function) and are standardised so that a score of 50 reflects the average of the general US population.\textsuperscript{15} The SF12-P scale was used as a secondary analysis because it includes the physical limitation questions described above, in addition to other covariates that were less related to the underlying construct of functional status.

#### Outcome: incident CVD

The outcome of interest was incident CVD, measured through the end of 2012. MESA participants were contacted by phone every 9 to 12 months and asked about interim cardiovascular events. Medical records, death certificates and next-of-kin interviews (for out-of-hospital cardiovascular deaths) were used by a team of two study cardiologists, cardiovascular epidemiologists or neurologists to determine the date of incident CVD.\textsuperscript{16} CVD was defined as an incident myocardial infarction, coronary revascularisation, resuscitated cardiac arrest, angina, stroke (fatal or non-fatal) or CVD death.\textsuperscript{17}

#### Covariates

All covariates were measured at the second examination (2002–2004). Demographic confounders included age, sex and income. Income was dichotomised for this analysis at earning US$75,000 per year. Additional covariates included smoking (never, former or current smoker), body mass index (BMI), total cholesterol, diabetes status and medication use. Diabetes status was categorised as normal, impaired fasting glucose or untreated diabetes and treated diabetes based on the 2003 American Diabetes Association fasting criteria algorithm.
Medications (antihypertensives and statins) were assessed by visual inspection of medication containers by study personnel or by self-report.

Statistical methods
Participants with missing data on SBP or physical limitations at examination 2, or on incident CVD status, were excluded, as were participants who had developed CVD by examination 2. We first stratified the study population by race/ethnicity, and summarised blood pressure, functional status and other covariates within each racial/ethnic group. Then we used Poisson models to estimate the incident rate ratios for incident CVD per 10 mm Hg higher SBP, using an offset for the person-time contributed until incident CVD, death or lost to follow-up. A likelihood ratio test provided evidence for a three-way interaction (on a multiplicative scale) between race/ethnicity, age and SBP (P=0.07), so we present models stratified on race/ethnicity.

All models were adjusted for age (as a linear term), sex and income. We ran separate sets of models for each modifier of interest: self-reported physical limitations, age and SF12-P score. We checked for a three-way interaction between SBP, physical limitations and age (<65 vs ≥65) in race-specific models, but did not find any evidence that the association between SBP and physical limitations on incident CVD varied by age category.

To assess modification on a multiplicative scale, we ran Poisson models stratified by functional status (eg, with physical limitations; without physical limitations; age <65; age ≥65) and by race/ethnicity to estimate the association between SBP (as a continuous measure) and CVD. We tested for interaction by running models with an interaction term between SBP and the measure of functional status. We explored the impact of adjusting for additional covariates (smoking, diabetes, antihypertensive medication, statins, total cholesterol, DBP and BMI) among white and black subgroups only, due to limited sample size. Due to conceptual concern over distinguishing confounders from mediators in the joint effects of SBP and functional status on CVD, we present the minimally adjusted models as our primary results.

We also explored the relationship between SBP and CVD by functional status on an additive scale, because departures from multiplicativity may result from different baseline levels of risk in the subgroups of interest. We ran Poisson models with SBP categorised into quintiles, in order to estimate the incidence rate of CVD at each quintile. Models of physical limitation were stratified (with limitations vs without limitations) and adjusted for age. In the models for age, incidence rates were estimated at the first and third quartile (ages 54 and 70, respectively). We used multivariable regression spline models to evaluate the best shape (linear or non-linear) of the trend in incidence rate across quintiles. We calculated slopes across quintiles to represent the average incidence rate difference (IRD) per quintile. All analyses were done in Stata V.13.1.

RESULTS
Our analysis excluded 584 participants who did not have a blood pressure measurement at examination 2, 14 participants who did not have physical function measures at examination 2, 5 participants with missing information on incident CVD and 3 participants who had prevalent CVD at examination 2. Excluded participants were older (mean age 67.9 vs 63.5), more likely to be male (61.2% vs 47.4%), less well educated (22.7% vs 36.7% with bachelor’s or higher), had lower incomes (2.0% vs 22.6% with income >US$75 000) and were more likely to report physical limitations (50.5% vs 27.3%). SBP, DBP and racial/ethnic distribution were similar among excluded and included participants. Among the analytic sample of 6117 participants, age at baseline ranged from 46 to 87. Participants were followed for an average of 8.8 years (until time of CVD incidence, death, loss to follow-up or 31 December 2012), during which time there were 557 incident cases of CVD detected.

White participants were older, more educated and had higher income levels than members of other racial/ethnic groups (table 1). Black participants had the highest mean SBP and were most likely to be on antihypertensive medications. Black participants were most likely to report physical limitations, while white participants were most likely to be diagnosed with CVD during follow-up.

We observed a generally weaker association between SBP and CVD among low-functioning subgroups (those with physical limitations or over age 65) compared with high-functioning subgroups (table 2). This pattern was most apparent among white participants, though there was a similar pattern among black participants that did not reach statistical significance for the interaction of SBP and physical limitations. Among Hispanic and Chinese participants, the association between SBP and CVD appeared not to be modified by measures of functional status. Among all racial/ethnic groups, higher SBP was associated with higher incidence of CVD. There was no evidence for an interaction between SBP, age and physical limitation among white (P=0.71) or black (P=0.22) participants. Sample sizes were insufficient to estimate the three-way interaction among Hispanic or Chinese participants.

The estimated CVD incidence rates by quintile of SBP revealed more nuances about the race/ethnicity-specific associations between SBP, functional status and CVD (figure 1). Among all racial/ethnic groups, the incidence of CVD was higher among low-functioning subgroups (with physical limitations or older age) than high-functioning subgroups (without physical limitations or younger age). Multivariable spline regression models reported that a linear fit was appropriate for the association between SBP and CVD in all subgroups.

Among white participants, the estimated increase in CVD per quintile higher SBP was smaller for those with physical limitations than for those without physical limitations (IRD 1.67 vs 3.35 per 1000 person-years). However, the average IRD across quintiles of SBP was slightly larger
among older whites (estimated at age 70) compared with younger whites (estimated at age 54). Among black participants, the association of SBP and CVD was weaker both among participants with physical limitations and among older participants, compared with those without physical limitations and younger participants. In contrast, among Hispanic participants, those with physical limitations and those of older age had larger IRDs (a larger increase in CVD incidence per quintile higher SBP) than those with no physical limitations and at younger ages, respectively. Large CIs limit generalisations among Chinese participants. Chinese participants were less likely to report physical limitations and less likely to develop CVD than other racial/ethnic groups, further hindering statistical power.

Adjustment for additional covariates resulted in generally attenuated but consistent results among white and black participants (figure 2). The adjusted association of SBP with CVD risk was statistically significant among those with high functional status, but approached unity in those with physical limitations or age ≥65.

Table 1  Characteristics of analytic sample at Multi-Ethnic Study of Atherosclerosis examination 2 by race/ethnicity

|                     | White  | Black  | Hispanic | Chinese | P value |
|---------------------|--------|--------|----------|---------|---------|
| N                   | 2421   | 1659   | 1320     | 717     |         |
| Age (years)         | 64.1   | 63.5   | 62.7     | 63.3    | <0.001  |
| Female              | 51.6%  | 54.9%  | 52.3%    | 51.3%   | 0.17    |
| Income              |        |        |          |         |         |
| <$US16 000          | 10.0%  | 19.9%  | 38.6%    | 44.5%   |         |
| US$16 000–US$39 999 | 21.2%  | 32.0%  | 35.3%    | 22.4%   |         |
| US$40 000–US$74 999 | 30.9%  | 30.1%  | 18.6%    | 15.4%   | <0.001  |
| US$75 000+          | 37.8%  | 18.0%  | 7.5%     | 17.7%   | <0.001  |
| Education           |        |        |          |         |         |
| High school or less | 21.1%  | 29.9%  | 63.7%    | 39.1%   |         |
| Some college or Associate’s | 27.8%  | 35.2%  | 26.0%    | 20.3%   |         |
| Bachelor’s or more  | 51.1%  | 34.9%  | 10.3%    | 40.6%   | <0.001  |
| BMI (kg/m²)         | 27.7   | 30.1   | 29.6     | 24.1    | <0.001  |
| Current smoker      | 10.9%  | 16.0%  | 10.2%    | 5.6%    | <0.001  |
| Total cholesterol (mg/dL) | 192.8  | 188.4  | 194.1    | 189.9   | <0.001  |
| Taking statins      | 23.5%  | 18.8%  | 16.6%    | 17.2%   | <0.001  |
| Diabetes            |        |        |          |         |         |
| Impaired fasting glucose | 17.9%  | 20.1%  | 21.7%    | 20.6%   |         |
| Treated diabetes    | 5.9%   | 16.6%  | 16.6%    | 11.2%   | <0.001  |
| DBP (mm Hg)         | 68.9   | 73.5   | 70.1     | 69.3    | <0.001  |
| Taking antihypertension medication | 37.8%  | 54.0%  | 37.3%    | 32.1%   | <0.001  |
| SBP, mean           | 121.0  | 130.2  | 125.0    | 120.7   | <0.001  |
| SBP quintiles       |        |        |          |         |         |
| Quintile 1 (60–107 mm Hg) | 24.3%  | 12.2%  | 20.7%    | 27.8%   |         |
| Quintile 2 (107.5–116.5 mm Hg) | 23.3%  | 16.8%  | 20.2%    | 19.4%   |         |
| Quintile 3 (117–127 mm Hg) | 19.2%  | 19.8%  | 18.7%    | 18.0%   |         |
| Quintile 4 (127.5–141 mm Hg) | 19.0%  | 23.7%  | 20.0%    | 18.6%   |         |
| Quintile 5 (141.5–230 mm Hg) | 14.2%  | 27.6%  | 20.5%    | 16.3%   | <0.001  |
| Self-reported physical limitations | 26.4%  | 31.7%  | 27.2%    | 20.8%   | <0.001  |
| Accomplished less than liked | 23.1%  | 27.8%  | 24.6%    | 19.1%   |         |
| Limited in work or daily activities | 17.2%  | 20.7%  | 21.8%    | 16.5%   |         |
| SF12-P score        | 49.9   | 47.8   | 47.9     | 48.9    | <0.001  |
| Incident CVD        | 10.2%  | 8.9%   | 9.2%     | 5.7%    | <0.01   |
| Mean time to CVD or end of follow-up (years) | 8.9      | 8.6      | 8.7      | 9.0      | <0.001  |

BMI, body mass index; CVD, cardiovascular disease; DBP, diastolic blood pressure; SBP, systolic blood pressure; SF12-P, Physical Component Summary score.
Using SF12-P scores to measure functional status produced similar patterns to those in figure 1 but with smaller differences between low-functioning (estimated at SF12-P=44.5) and high-functioning (SF12-P=55.5) groups (see online supplementary appendix figure 1).

**DISCUSSION**

Overall, we observed attenuated associations between SBP and incident CVD among those with low functional status (measured by self-reported physical limitations and by chronological age) among white and black adults. This pattern was generally consistent across both multiplicative and additive scales using self-reported physical limitations, but not age (as older white participants had a slightly larger increase in risk per quintile higher SBP than younger white participants). Our findings are consistent with previous research that has found attenuated or inverted associations between blood pressure and health outcomes among low-functioning subgroups (defined by age, walking speed or limitations in activities of daily living).

Blood pressure treatment guidelines and randomised controlled trials have frequently used age to define treatment targets or populations of interest. Chronic age is an imprecise measure of functional status, though it is easily and routinely collected. Others have recognised the limitations of relying on chronological age to predict health-related outcomes. Among white participants, using self-reported physical limitations as a measure of functional status provided consistent evidence of attenuated associations between SBP and incident CVD among adults with physical limitations across multiplicative and additive scales, while there was not an attenuated association between SBP and incident CVD among older adults.

**Table 2** Estimated associations (incident rate ratio (IRR)* per 10 mm Hg higher systolic blood pressure (SBP) between SBP and incident cardiovascular disease (CVD) by measures of functional status and racial/ethnic group

|          | No physical limitations | With physical limitations | Age <65 | Age ≥65 |
|----------|------------------------|--------------------------|---------|---------|
| Overall  |                        |                          |         |         |
| N        | 4446                   | 1671                     | 3218    | 2899    |
| IRR      | 1.21                   | 1.10                     | 1.30    | 1.11    |
| 95% CI   | 1.16 to 1.27           | 1.03 to 1.17             | 1.22 to 1.39 | 1.06 to 1.17 |
| P value for interaction | 0.04                    | <0.01                    |         |         |
| White    |                        |                          |         |         |
| N        | 1783                   | 638                      | 1229    | 1192    |
| IRR      | 1.29                   | 1.09                     | 1.33    | 1.17    |
| 95% CI   | 1.19 to 1.40           | 0.99 to 1.20             | 1.18 to 1.49 | 1.01 to 1.07 |
| P value for interaction | <0.01                    | <0.01                    |         |         |
| Black    |                        |                          |         |         |
| N        | 1134                   | 525                      | 864     | 795     |
| IRR      | 1.25                   | 1.10                     | 1.36    | 1.10    |
| 95% CI   | 1.14 to 1.37           | 0.96 to 1.25             | 1.22 to 1.52 | 1.00 to 1.21 |
| P value for interaction | 0.14                    | <0.01                    |         |         |
| Hispanic |                        |                          |         |         |
| N        | 961                    | 359                      | 740     | 580     |
| IRR      | 1.11                   | 1.10                     | 1.13    | 1.08    |
| 95% CI   | 1.00 to 1.23           | 0.95 to 1.27             | 0.97 to 1.31 | 0.98 to 1.19 |
| P value for interaction | 0.89                    | 0.66                     |         |         |
| Chinese  |                        |                          |         |         |
| N        | 568                    | 149                      | 385     | 332     |
| IRR      | 1.21                   | 1.23                     | –†      | 1.10    |
| 95% CI   | 1.01 to 1.44           | 0.95 to 1.58             | –†      | 0.94 to 1.29 |
| P value for interaction | 0.93                    | –                        |         |         |

*From Poisson models with offset for person-time contributed until incident CVD, death or loss to follow-up. Models for physical limitations were adjusted for age (continuous), gender and income (dichotomised at US$75 000). Models by age category were adjusted for gender and income (dichotomised at US$75 000).
†Omitted due to small number of events (<10).
adults on an additive scale. Among blacks, both older age and physical limitations revealed attenuated associations between SBP and CVD on both multiplicative and additive scales (though not statistically significant for physical limitations on a multiplicative scale). Additionally, across all race/ethnic groups, those with physical limitations had higher incidence of CVD at all levels of SBP than those without physical limitations, after adjusting for age. Where feasible, self-reported physical limitations or other specific measures of functional status may be a useful addition to methods of assessing risk in clinical settings.

Figure 1  Estimated incidence rates of cardiovascular disease by quintile of systolic blood pressure, by measures of functional status and race/ethnicity. PY, per 1000 person years.
between SBP and CVD were similar by functional status on a multiplicative scale, and on an additive scale appeared to be stronger (larger average IRDs across quintiles of SBP) for those with physical limitations and those at higher ages than those without physical limitations and at lower ages, respectively. Hispanic participants were also the youngest of the racial/ethnic groups in MESA. Previous research in a Hispanic population found that the association between SBP and all-cause mortality was attenuated among slow walkers compared with fast walkers; however, these participants were older (mean age 70.5 years) and less healthy overall (mean SBP 139 mm Hg, 22.8% on diabetes medication) than MESA’s Hispanic participants (mean age 62.7 years, mean SBP 125 mm Hg, 16.3% on diabetes medication). Future research should continue to investigate patterns of SBP and CVD risk among diverse minority populations.

Some limitations are important to consider. Self-reported physical limitations, assessed by two questions, is a crude measure of functional status; more objective measures may demonstrate even better discrimination in CVD risk. Additionally, previous research has shown that the health risks of high SBP among those with functional impairments may be stronger among older adults than among middle-aged adults. We did not find any evidence that the association between SBP and physical limitations varied by age (<65 vs ≥65), though we may have been underpowered to detect heterogeneity statistically.

Additionally, more research is needed to inform how observed differences in CVD risk associated with SBP should influence treatment of high blood pressure. The biological mechanism mediating an attenuated association between high blood pressure and outcomes among low-functioning older adults remains uncertain, although there are several plausible explanations. Poor physical functioning may be associated with compromised haemodynamic regulation, vascular stiffening and insufficient cerebral, myocardial or renal perfusion, resulting in poorer health outcomes independent of SBP. Others have noted the challenges in accurate measurement of blood pressure in older adults, due to orthostatic hypotension, pseudohypertension and postprandial hypertension, suggesting that attenuated association with outcomes may reflect measurement error. Another possibility is that treatment of high blood pressure, which often requires multiple medications, could result in polypharmacy or other adverse events such as falls and fractures, and these adverse events could initiate a cascade of events that could result in hospitalisation, morbidity and even death. Thus, observed low blood pressures may be correlated to poorer outcomes. Our analysis shows that future studies that evaluate benefits of treating high blood pressure...
should explore patterns by race/ethnicity as well as functional status.

The presence of racial/ethnic variation in associations between SBP, incident CVD and functional status do not imply biologically predetermined differences in risks; rather, our findings should caution against generalising results from predominantly white study populations to other racial/ethnic populations. The observed differences that we found are likely the result of broad social and environmental influences throughout the life course that are strongly patterned by racial/ethnic identity in the USA. However, these findings are also novel and, if replicated, much more research is needed to understand the causal pathways resulting in racial/ethnic heterogeneity in associations between SBP, functional status and CVD.

In summary, we found that the risk of incident CVD associated with high blood pressure appears to be attenuated among white and black adults with physical limitations and at older ages in a diverse cohort of middle aged and older adults. Patterns among Hispanic and Chinese adults were less clear, which likely reflects limited sample sizes. Understanding how functional status (or factors underlying functional impairments) influence CVD risk across racial/ethnic groups could be useful for identifying at-risk persons and informing public health strategies to improve health and reduce CVD risk.

Author affiliations
1School of Biological and Population Health Sciences, Oregon State University, Corvallis, Oregon, USA
2Department of Medicine, Epidemiology and Biostatistics, University of California, San Francisco, California, USA
3Department of Biostatistics, University of Washington, Seattle, Washington, USA
4General Internal Medicine Section, Veterans Affairs Medical Center, San Francisco, California, USA
5Cardiovascular Health Research Unit, Departments of Medicine, Epidemiology, and Health Services, University of Washington and Kaiser Permanente Washington Health Research Institute, Seattle, Washington, USA

Acknowledgements
The authors thank the other investigators, the staff and the participants of the MESA study for their valuable contributions. A full list of participating MESA investigators and institutions can be found at http://www.mesa-nhbi.org.

Contributors
PK developed the initial research question, conducted all analyses and drafted the manuscript. MCO provided oversight, including review of analyses and editing the manuscript. CP, RK, MS and BMP reviewed the results and provided guidance on interpretation, and provided comments on multiple drafts of the manuscript.

Funding
This research was supported by grants K01AG039387 and R01AG46206 from the National Institute on Aging; contracts HHSN268201500003l, N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168 and N01-HC-95169 from the National Heart, Lung, and Blood Institute, and grants UL1-TR-000040, UL1-TR-000179 and UL1-TR-001420 from NCATS.

Competing interests
None declared.

Patient consent
Obtained.

Ethics approval
IRBs at each participating site.

Provenance and peer review
Not commissioned; externally peer reviewed.

Data sharing statement
No additional unpublished data are available. More information about MESA, including all participating MESA investigators and institutions, can be found at http://www.mesa-nhbi.org.
20. Wright JT, Williamson JD, Whelton PK, et al. A randomized trial of intensive versus standard blood-pressure control. *N Engl J Med* 2015;373:2103–16.
21. Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. *N Engl J Med* 2008;358:1887–98.
22. Turnbull F, Neal B, Nino-Murcia M, et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. *BMJ* 2008;336:1121–3.
23. Levine ME. Modeling the rate of senescence: can estimated biological age predict mortality more accurately than chronological age? *J Gerontol A Biol Sci Med Sci* 2013;68:867–74.
24. Morley JE. Systolic hypertension should not be treated in persons aged 80 and older until blood pressure is greater than 160 mmHg. *J Am Geriatr Soc* 2013;61:1197–8.
25. Tinetti ME, Han L, Lee DS, et al. Antihypertensive medications and serious fall injuries in a nationally representative sample of older adults. *JAMA Intern Med* 2014;174:588–95.